year
million
peopl
afflict
influenzaassoci
respiratori
tract
infect
lead
patient
seek
outpati
medic
attent
refer
medic
attend
acut
respiratori
infect
ari
rapid
accur
costeffect
method
need
maxim
clinic
benefit
antivir
reduc
inappropri
antibiot
usag
new
assay
method
use
multiplex
revers
transcriptas
polymeras
chain
reaction
mrtpcr
avail
allow
rel
rapid
detect
multipl
viru
type
includ
influenza
influenza
season
center
diseas
control
prevent
cdc
fund
multicent
us
influenza
vaccin
effect
flu
network
conduct
studi
design
determin
effect
season
influenza
vaccin
studi
use
singleplex
rtpcr
srtpcr
detect
influenza
viru
univers
pittsburgh
site
flu
network
also
use
mrtpcr
purpos
studi
compar
agreement
srtpcr
mrtpcr
influenza
viru
detect
us
flu
network
evalu
effect
season
influenza
vaccin
use
testneg
casecontrol
studi
design
proport
vaccin
among
test
posit
influenza
compar
proport
vaccin
among
test
neg
particip
current
studi
enrolle
univers
pittsburgh
site
flu
studi
describ
previous
elig
criteria
includ
patient
age
month
seek
outpati
medic
care
upper
respiratori
ill
day
durat
cough
take
influenza
antivir
visit
prospect
studi
approv
univers
pittsburgh
institut
review
board
nasal
oropharyng
mucosa
sampl
use
polyest
swab
combin
cryovial
deliv
upmc
clinic
virolog
laboratori
within
hour
specimen
store
lysi
buffer
aliquot
nucleic
acid
isol
detect
influenza
viru
use
cdc
singleplex
rtpcr
srtpcr
test
mrtpcr
test
use
esensor
instrument
respiratori
viral
panel
genmark
diagnost
inc
toto
specimen
collect
test
presenc
influenza
use
srtpcr
fund
avail
analyz
mrtpcr
specimen
srtpcrposit
influenza
random
sampl
specimen
srtpcrneg
influenza
total
specimen
doubli
assay
purpos
studi
compar
agreement
srtpcr
mrtpcr
influenza
viru
detect
srtpcr
mrtpcr
extract
assay
method
previous
publish
esensor
rvp
mrtpcr
assay
genmark
diagnost
use
studi
current
approv
clinic
use
europ
methodolog
characterist
broader
rang
viral
analyt
us
fdaclear
version
includ
season
influenza
viru
subtyp
influenza
b
viru
measur
agreement
srtpcr
mrtpcr
influenza
assay
determin
use
cohen
kappa
statist
analys
conduct
use
sa
version
sa
institut
inc
cari
nc
among
ari
patient
influenza
viru
detect
specimen
influenza
b
viru
detect
specimen
use
srtpcr
influenza
viru
detect
specimen
influenza
b
viru
detect
specimen
use
mrtpcr
signific
agreement
influenza
result
assay
influenza
kappa
confid
interv
ci
chisquar
p
influenza
b
kappa
ci
chisquar
p
overal
result
kappa
ci
chisquar
p
sensit
specif
respect
influenza
influenza
b
srtpcr
treat
gold
standard
tabl
mean
cycl
threshold
ct
valu
srtpcr
influenza
standard
deviat
n
influenza
b
n
among
srtpcr
posit
mrtpcr
neg
influenza
ct
valu
rang
data
avail
sd
influenza
mean
suggest
weak
posit
two
srtpcr
influenza
posit
mrtpcr
neg
also
posit
anoth
viru
multiplex
assay
respiratori
syncyti
viru
human
rhinoviru
among
srtpcr
posit
mrtpcr
neg
influenza
b
ct
valu
rang
data
avail
sd
influenza
b
mean
suggest
weak
posit
three
srtpcr
influenza
b
posit
mrtpcr
neg
also
posit
anoth
viru
multiplex
assay
respiratori
syncyti
viru
coronaviru
fortyseven
percent
discord
result
concord
result
person
vaccin
mean
ct
valu
ribonucleas
p
rnasep
protein
may
reflect
sampl
qualiti
person
pcr
neg
versu
pcr
posit
one
person
mrtpcr
posit
influenza
srtpcr
neg
rnasep
valu
suggest
sampl
qualiti
good
rnasep
valu
srtpcr
posit
mrtpcr
neg
rang
specimen
higher
level
sd
rnasep
valu
posit
suggest
sampl
qualiti
good
major
specimen
studi
offer
abil
compar
influenza
detect
use
two
assay
winter
influenza
season
b
strain
circul
unabl
test
inclus
sampl
ari
specimen
mrtpcr
howev
sampl
size
strength
sensit
specif
analysi
suffici
allow
confid
use
mrtpcr
detect
influenza
b
virus
studi
support
similar
srtpcr
mrtpcr
detect
influenza
viru
among
patient
seek
outpati
care
acut
respiratori
ill
